EHA 2021
THE EUROPEAN HEMATOLOGY ASSOCIATION 2021 VIRTUAL CONGRESS
June 9-17, 2021 | Virtual
The updated guidelines for the novel AML agents
A+AVD as a desirable treatment option for patients with previously untreated stage III/IV CHL: A 5-year update of the phase 3 ECHELON-1 study
Ravulizumab for adult patients with PNH and HDA: Two-year results from phase 3, open-label study
The beyond study: Luspatercept demonstrates sustained clinical benefits in NTDT
C+R as an option for treating relapsed INHL patients: Phase 3 CHRONOS-3 study results
Tisagenlecleucel—A promising therapy for RRFL in adult patients: Primary analysis of phase 2 ELARA trial
Updates on the ERNEST demonstrate the survival effects of ruxolitinib on MF patients